Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER (+) breast cancer

(2013) Nicola Napoli et al.   BONE

Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis

(2013) Duveken B.Y. Fontein et al.   JOURNAL OF CLINICAL ONCOLOGY

Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples

(2013) Lieke van Huis-Tanja et al.   PHARMACOGENOMICS

Multiple Testing for Exploratory Research

(2012) Jelle J. Goeman et al.   STATISTICAL SCIENCE

The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia

(2011) Miyuki Kanematsu et al.   BMC CANCER

Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer

(2011) In Hae Park et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Losing balance: Hardy–Weinberg disequilibrium as a marker for recurrent loss-of-heterozygosity in cancer

(2011) Katherine Wilkins et al.   HUMAN MOLECULAR GENETICS

Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women

(2011) Anne Hege Straume et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

(2011) Cornelis JH van de Velde et al.   LANCET

Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors

(2010) L. Wang et al.   CANCER RESEARCH

Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors

(2010) James N. Ingle et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotyping of DNA Samples Isolated from Formalin-Fixed Paraffin-Embedded Tissues Using Preamplification

(2010) Renee Baak-Pablo et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Managing the toxicities of the aromatase inhibitors

(2009) Joanne E Mortimer   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women

(2009) Hui Cai et al.   Pharmacogenetics and Genomics

Using germline genotype in cancer pharmacogenetic studies

(2009) Sarah R McWhinney et al.   PHARMACOGENOMICS

A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma

(2008) R. Colomer et al.   CLINICAL CANCER RESEARCH

Prospective Study to Assess Short-Term Intra-Articular and Tenosynovial Changes in the Aromatase Inhibitor–Associated Arthralgia Syndrome

(2008) Leilani Morales et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial

(2008) Jack Cuzick et al.   LANCET ONCOLOGY